Bioequivalence of two pharmaceutical forms of diltiazem

Publisher Website
Google Scholar
Abstract
Diltiazem, a calcium‐channel blocking agent, has been shown to be a potent coronary vasodilator used in the treatment of ischaemic heart disease. The present study was conducted to compare the bioavailability of regular 60 mg tablets administered every 6 h with sustained release capsules of 120 mg administered every 12 h. High‐performance liquid chromatographic analysis was carried out for determination of diltiazem and one of its metabolites desacetildiltiazem in six male patients. The relative bioavailability of this sustained‐release pharmaceutical form did not show any significant difference with that of tablets.